» Articles » PMID: 38003333

Pharmacokinetics and Changes in Lipid Mediator Profiling After Consumption of Specialized Pro-Resolving Lipid-Mediator-Enriched Marine Oil in Healthy Subjects

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Nov 25
PMID 38003333
Authors
Affiliations
Soon will be listed here.
Abstract

Omega-3 polyunsaturated fatty acids (PUFAs) play a vital role in human health, well-being, and the management of inflammatory diseases. Insufficient intake of omega-3 is linked to disease development. Specialized pro-resolving mediators (SPMs) are derived from omega-3 PUFAs and expedite the resolution of inflammation. They fall into categories known as resolvins, maresins, protectins, and lipoxins. The actions of SPMs in the resolution of inflammation involve restricting neutrophil infiltration, facilitating the removal of apoptotic cells and cellular debris, promoting efferocytosis and phagocytosis, counteracting the production of pro-inflammatory molecules like chemokines and cytokines, and encouraging a pro-resolving macrophage phenotype. This is an experimental pilot study in which ten healthy subjects were enrolled and received a single dose of 6 g of an oral SPM-enriched marine oil emulsion. Peripheral blood was collected at baseline, 3, 6, 9, 12, and 24 h post-administration. Temporal increases in plasma and serum SPM levels were found by using LC-MS/MS lipid profiling. Additionally, we characterized the temporal increases in omega-3 levels and established fundamental pharmacokinetics in both aforementioned matrices. These findings provide substantial evidence of the time-dependent elevation of SPMs, reinforcing the notion that oral supplementation with SPM-enriched products represents a valuable source of essential bioactive SPMs.

Citing Articles

The intricate interplay between ferroptosis and efferocytosis in cancer: unraveling novel insights and therapeutic opportunities.

Firouzjaei A, Mohammadi-Yeganeh S Front Oncol. 2024; 14:1424218.

PMID: 39544291 PMC: 11560889. DOI: 10.3389/fonc.2024.1424218.


Role and mechanism of specialized pro-resolving mediators in obesity-associated insulin resistance.

Liu X, Tang Y, Luo Y, Gao Y, He L Lipids Health Dis. 2024; 23(1):234.

PMID: 39080624 PMC: 11290132. DOI: 10.1186/s12944-024-02207-9.


Synbiotic DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study.

Speckmann B, Wagner T, Jordan P, Werz O, Wilhelm M, Tom Dieck H Nutrients. 2024; 16(9).

PMID: 38732601 PMC: 11085393. DOI: 10.3390/nu16091354.

References
1.
Ji R . Specialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch. Annu Rev Pharmacol Toxicol. 2022; 63:273-293. PMC: 10290889. DOI: 10.1146/annurev-pharmtox-051921-084047. View

2.
Dalli J, Chiang N, Serhan C . Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. Nat Med. 2015; 21(9):1071-5. PMC: 4560998. DOI: 10.1038/nm.3911. View

3.
Regidor P, De La Rosa X, Muller A, Mayr M, Gonzalez Santos F, Gracia Banzo R . PCOS: A Chronic Disease That Fails to Produce Adequately Specialized Pro-Resolving Lipid Mediators (SPMs). Biomedicines. 2022; 10(2). PMC: 8962413. DOI: 10.3390/biomedicines10020456. View

4.
Claria J, Serhan C . Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A. 1995; 92(21):9475-9. PMC: 40824. DOI: 10.1073/pnas.92.21.9475. View

5.
Irun P, Gracia R, Piazuelo E, Pardo J, Morte E, Pano J . Serum lipid mediator profiles in COVID-19 patients and lung disease severity: a pilot study. Sci Rep. 2023; 13(1):6497. PMC: 10118224. DOI: 10.1038/s41598-023-33682-2. View